Table 1 Baseline characteristics, all patients
All patients (N = 521) | |
|---|---|
Age | |
Years, median (range) | 66.3 (39-86) |
≥ 70 years, n (%) | 188 (36.1) |
Gender, n (%) male | 363 (69.7) |
Origin, n (%) Caucasian | 514 (98.7) |
Weight, kg [mean (SD)] | 74.9 (14.45) |
Smoking status, n (%) | |
Current smoker | 139 (26.7) |
Ex-smoker | 243 (46.6) |
Never smoked | 138 (26.5) |
Missing data | 1 ( 0.2) |
Histology, n (%) | |
Non-squamous cell carcinoma | 444 (85.2) |
Squamous cell carcinoma a | 77 (14.8) |
Disease stage at study entry, n (%) | |
Stage IIIa | 35 ( 6.7) |
Stage IIIb | 103 (19.8) |
Stage IV | 383 (73.5) |
All patients (N = 521) | |
Karnofsky Index (KI), n (%) | |
KI ≥ 80% | 323 (62.0) |
KI 70% | 134 (25.7) |
KI 60% | 45 ( 8.6) |
KI 50% | 18 ( 3.5) |
Missing data | 1 ( 0.2) |
Type of previous first-line chemotherapy | |
Platinum-based combinations, n (%) | 450 (86.4) |
Platinum-free combinations, n (%) | 12 ( 2.3) |
Single-agent, n (%) | 59 (11.3) |
Most frequent agents used (at least 10% of patients), n (%)b | |
Carboplatin | 327 (62.8) |
Cisplatin | 135 (25.9) |
Vinorelbine | 162 (31.1) |
Gemcitabine | 159 (30.5) |
Paclitaxel | 131 (25.1) |
Duration of previous first-line chemotherapy, months [median (range)] | 3.5 (0-32) |
Time elapsed since previous first-line chemotherapy, months [median (range)] | 3.9 (0-74) |
Patients [n (%)] who started pemetrexed | |
Immediately after end of first-line treatmentc | 82 (15.7) |
Within 3 months after end of first-line treatmentd | 132 (25.3) |
More than 3 months after end of first-line treatmente | 302 (58.0) |
Missing data | 5 (1.0) |